

Systemic Aspergillosis and Systemic Candidiasis Market to Reach \$8.63 Billion by 2028

The Business Research Company's Systemic Aspergillosis and Systemic Candidiasis Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 3, 2024 /EINPresswire.com/ -- The systemic aspergillosis and systemic candidiasis market size has grown strongly in recent years. It will grow



from \$6.82 billion in 2023 to \$7.2 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. It will grow to \$8.63 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to the increasing incidence of fungal infections, an immunocompromised patient population, improved diagnostic technologies, the rise in invasive

"

You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs "

> The Business Research Company

medical procedures, and the global spread of infections.

Increase in Incidence of Fungal Diseases Driving Market Growth

The increase in the incidence of fungal diseases is expected to propel the growth of the systemic aspergillosis and systemic candidiasis market going forward. Fungal diseases refer to infections caused by fungi that can affect various body parts, resulting in multiple symptoms and

complications. These diseases include cutaneous skin infections, respiratory infections, and systemic infections. Fungal diseases are treated with antifungal medications such as oral azoles, voriconazole, and liposomal amphotericin B. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, the clinical cases of Candida auris, an emerging fungus, increased from 476 in 2019 to 1,471 in 2021. Screening cases increased threefold from 2020 to 2021, to 4,041. Therefore, the increase in the incidence of fungal disease is driving the growth of the systemic aspergillosis and systemic candidiasis market.

Explore comprehensive insights into the systemic aspergillosis and systemic candidiasis market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=12148&type=smp

Key Players and Market Trends

Major companies operating in the systemic aspergillosis and systemic candidiasis market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd., Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., NovaDigm Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC

Focus on Next-Generation Anti-Fungal Drug Agents

Major companies operating in the systemic aspergillosis and systemic candidiasis market are focusing on advanced solutions, such as next-generation anti-fungal drug agents, to meet the growing demand for more effective and targeted treatments. Next-generation anti-fungal drug agents refer to advanced medications designed to combat fungal infections more effectively, often leveraging innovative mechanisms or formulations to enhance efficacy and reduce resistance. For instance, in October 2023, BDR Pharmaceutical, a US-based pharmaceutical company, launched Zisavel capsules for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the family of isavuconazole, a class of medications called azole antifungals. Isavuconazole plays an important role in the treatment of invasive aspergillosis. The product will be available in 100 mg capsules and is the first line of treatment for the aforementioned fungal infections.

Segments:

•Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types

Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
End User: Clinic, Hospital, Other End Users

Geographical Insights: North America Leading the Market

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Make your report purchase here and explore the whole industry's data as well

https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemiccandidiasis-global-market-report

<u>Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2024</u> from TBRC covers the following information:

•Market size data for the forecast period: Historical and Future

•Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

•Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on systemic aspergillosis and systemic candidiasis market size, systemic aspergillosis and systemic candidiasis market drivers and trends, systemic aspergillosis and systemic candidiasis market major players, competitors' revenues, market positioning, and market growth across geographies. The systemic aspergillosis and systemic candidiasis market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Candidiasis Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-marketreport

Aspergillosis Treatment Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-</u> <u>report</u>

Invasive Fungal Infections Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-</u> <u>report</u>

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help

its users assess supply-demand gaps.

Contact Information The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/724788565

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.